GlassScriptPhysician profile
Joshua E Christian
NPI 1386035095
$1,425.40
in general payments reported to CMS, 2019-2025
12 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $376 · 2023: $435 · 2024: $232 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $811.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $391.26 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $282.72 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $163.57 | 2021-2023 | Caplyta |
| Neurocrine Biosciences, INC. | $151.96 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $110.46 | 2022-2024 | Invega Trinza, Invega Sustenna |
| Boston Scientific Corporation | $79.79 | 2021-2023 | Infinion 16 |
| Teva Pharmaceuticals USA, INC. | $78.63 | 2022-2025 | Uzedy |
| Vanda Pharmaceuticals INC. | $54.83 | 2021-2022 | |
| Indivior INC. | $40.16 | 2023 | Perseris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $39.73 | 2021-2024 | |
| Bioxcel Therapeutics, INC. | $16.92 | 2023 | Igalmi |
| Olympus America INC. | $15.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Christian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.